CD8A and tetanus: Following the tracks of an early study proposing tetanus-diphtheria vaccine antigens as sources of protective cross-reactive immunity to SARS-CoV-2 (47, 48), in this exploratory work we show proof that Td vaccine can prime T cells cross-reacting with known SARS-CoV-2-specific CD8+ T cell epitopes.